ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0478 • ACR Convergence 2020

    Increasing Awareness of Advocacy During Early Career – a Web-Based Educational Program

    Sirisha Gokaraju1, Angus Worthing2, Katherine Maher3, Grace Wright4 and Gail Kerr5, 1Georgetown University hospital, Bethesda, MD, 2Arthritis & Rheumatism Associates, PC, Washington, DC, 3Arthritis & Rheumatism Associates, PC, Alexandria, VA, 4Association of Women in Rheumatology, New York, NY, 5Washington DC VA Medical Center, Washington, DC

    Background/Purpose: In 2015, the American College of Rheumatology (ACR) began Advocacy 101 in person-education for Fellows in Training (FIT) and physicians to encourage participation in…
  • Abstract Number: 0473 • ACR Convergence 2020

    Characterization of DOCK8 as a Novel Gene Associated with Cytokine Storm Syndrome

    Mingce Zhang1, Remy Cron2, Devin Absher3, Prescott Atkinson1, Winn Chatham1 and Randy Cron1, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, 3HudsonAlpha Institute for Biotechnology, Huntsville, AL

    Background/Purpose: Cytokine storm syndrome (CSS), also known as macrophage activation syndrome (MAS) or secondary hemophagocytic lymphohistiocytosis (HLH), is a life threatening condition that commonly presents…
  • Abstract Number: 0487 • ACR Convergence 2020

    Association Between an Extended Lifestyle Score and Adverse Health-related Outcomes in People with Rheumatoid Arthritis: A Study of 5295 UK Biobank Participants

    Jordan Canning1, Stefan Siebert2, Bhautesh Jani1, Frances Mair1 and Barbara Nicholl1, 1University of Glasgow, Glasgow, Scotland, United Kingdom, 2University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterised by inflammation of the synovial joints. Traditional lifestyle factors, such as smoking and poor diet,…
  • Abstract Number: 0486 • ACR Convergence 2020

    Differences in Low-density Lipoprotein (LDL) Particle Composition and Oxidation May Underlie the Paradoxical Association of Low LDL with Higher Coronary Atherosclerosis Burden in Rheumatoid Arthritis

    George Karpouzas1, Sarah Ormseth1, Elizabeth Hernandez1 and Matthew Budoff1, 1Harbor-UCLA Medical Center and the Lundquist Institute, Torrance, CA

    Background/Purpose: Rheumatoid arthritis (RA) patients in the lowest LDL group (< 70mg/dl) experience unexpectedly high cardiovascular risk. We first explored whether this group (Group 1)…
  • Abstract Number: 0492 • ACR Convergence 2020

    Microbiota-induced Intestinal Barrier Dysfunction Initiates the Shuttling of Immune Cells from the Gut to the Joints

    Narges Tajik1, Michael Frech2, Carolin Brandl1, Juan Cañete3, Francesco Ciccia4, Georg Schett5 and Mario Zaiss6, 1Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany; 2 Deutsches Zentrum für Immuntherapie (DZI), Erlangen, Germany, 2Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany; 2 Deutsches Zentrum für Immuntherapie (DZI), Erlangen, 3Departamento de Reumatología, Hospital Clínic de Barcelona e IDIBAPS, Barcelona, Spain, Barcelona, Spain, 4Dipartimento Biomedico di Medicina Interna e Specialistica, University of Palermo, Palermo, Italy, Palermo, Italy, 5Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, 6Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany

    Background/Purpose: While it is known that microbial dysbiosis is associated with the onset of rheumatoid arthritis, mechanistic insights how it facilitates the development of arthritis…
  • Abstract Number: 0491 • ACR Convergence 2020

    Relationship Between Rheumatoid Arthritis and Pulmonary Function in the UK Biobank

    Lauren C. Prisco1, Matthew Moll1, Jiaqi Wang2, Weixing Huang3, Lily Martin1, Vanessa Kronzer4, Sicong Huang2, Edwin Silverman2, Tracy J. Doyle5, Michael Cho5 and Jeffrey Sparks6, 1Brigham and Women's Hospital, Boston, 2Brigham and Women's Hospital, Boston, MA, 3Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, 4Mayo Clinic, Rochester, MN, 5Brigham and Women's Hospital, West Roxbury, MA, 6Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Established pulmonary manifestations of RA include restrictive processes such as interstitial lung disease and obstructive processes such as bronchiectasis, but clinically detected forms of…
  • Abstract Number: 0497 • ACR Convergence 2020

    Interleukin-23 Acts Directly on Podocytes and Contributes to the Development of Glomerulonephritis

    Shui Lian Yu1, Hao Li1, Abhigyan Satyam1, Shawn Rose2, Jarrat Jordan3 and George Tsokos4, 1Division of Rheumatology & Clinical Immunology/Beth Israel Deaconess Medical Center/Harvard Medical School, boston, 2Rheumatology & Autoimmunity Translational Medicine at Janssen Pharmaceuticals, boston, 3Janssen Research & Development, LLC, Spring House, PA, 4Division of Rheumatology & Clinical Immunology/Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA

    Background/Purpose: Interleukin (IL)-23 is central in the advancement of an inflammatory response and has been shown to be involved in the pathogenesis of autoimmune diseases.…
  • Abstract Number: 0499 • ACR Convergence 2020

    WITHDRAWN

  • Abstract Number: 0494 • ACR Convergence 2020

    Genetic-epigenetic Interaction and the Relationship Between DNA Methylation Patterns and Disease Activity in a Longitudinal Cohort of Lupus Patients

    Patrick Coit1, Lourdes Ortiz-Fernandez2, Emily Lewis3, W. Joseph McCune3, Kathleen Maksimowicz-McKinnon4 and Amr Sawalha2, 1University of Pittsburgh and University of Michigan, Pittsburgh, PA, 2University of Pittsburgh, Pittsburgh, PA, 3University of Michigan, Ann Arbor, MI, 4Henry Ford Hospital, Detroit

    Background/Purpose: Genetic factors and epigenetic dysregulation are implicated in the pathogenesis of lupus. We performed a longitudinal analysis of DNA methylation in lupus patients for…
  • Abstract Number: 0489 • ACR Convergence 2020

    Prevalence, Incidence, and Cause-Specific Mortality of Rheumatoid Arthritis-Associated Interstitial Lung Disease Among Older Patients with Rheumatoid Arthritis: A Nationwide Cohort Study

    Jeffrey Sparks1, Yinzhu Jin1, Soo-Kyung Cho2, Seanna Vine1, Rishi Desai1, Tracy J. Doyle3 and Seoyoung Kim1, 1Brigham and Women's Hospital, Boston, MA, 2Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 3Brigham and Women's Hospital, West Roxbury, MA

    Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is one of the most serious extra-articular RA manifestations and is more common in older patients. Registry-based RA-ILD…
  • Abstract Number: 0502 • ACR Convergence 2020

    Integration of Clinical and Protein Markers Through Machine Learning to Distinguish Patients with Psoriasis Arthritis from Those with Psoriasis Without Psoriatic Arthritis

    Sara Rahmati1, Fatima Abji1, Proton Rahman2 and Vinod Chandran3, 1University Health Network, Toronto, ON, Canada, 2Memorial University of Newfoundland, Department of Medicine, St John's, Canada, 3Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Psoriatic Arthritis (PsA) is a progressive inflammatory arthritis that occurs in about 24% of psoriasis patients. Early diagnosis of PsA is associated with better…
  • Abstract Number: 0505 • ACR Convergence 2020

    Secukinumab Provides Sustained Improvements in Clinical and Imaging Outcomes in Patients with Psoriatic Arthritis and Axial Manifestations: Results from the MAXIMISE Trial

    Xenofon Baraliakos1, Laure Gossec2, Effie Pournara3, Slawomir Jeka4, Ricardo Blanco5, Salvatore D'Angelo6, Georg Schett7, Barbara Schulz3, Michael Rissler3, Dermot Whyms8, Chiara Perella3 and Laura Coates9, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, 2Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, 3Novartis Pharma AG, Basel, Switzerland, 42nd Univ Hospital, CM UMK, Bydgoszcz, Poland, 5Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, 6Rheumatology Department of Lucania and Rheumatology Institute of Lucania (IRel), San Carlo Hospital of Potenza, Potenza, Italy, 7Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, 8Novartis Ireland Limited, Dublin, Ireland, 9University of Oxford, Oxford, United Kingdom

    Background/Purpose: Axial disease may affect up to 25–70% of psoriatic arthritis (PsA) patients, depending on the definition used. Current evidence on efficacy of biologics in…
  • Abstract Number: 0506 • ACR Convergence 2020

    Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19-Subunit of Interleukin-23, Through Week 52 of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis

    Iain McInnes1, Proton Rahman2, Alice Gottlieb3, Elizabeth Hsia4, Alexa Kollmeier5, Xie Xu6, Ramanand Subramanian7, Prasheen Agarwal7, Shihong Sheng7, Yusang Jiang7, Bei Zhou7, Désirée van der Heijde8 and Philip Mease9, 1Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, 2Memorial University of Newfoundland, Department of Medicine, St John's, Canada, 3Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, 4Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, 5Janssen Research & Development, LLC, La Jolla, CA, 6Janssen Research & Development, LLC, San Marcos, CA, 7Janssen Research & Development, LLC, Spring House, PA, 8Leiden University Medical Center, Leiden, Netherlands, 9Seattle Rheumatology Associates, P.L.L.C., Seattle, WA

    Background/Purpose: Guselkumab (GUS), a monoclonal antibody that specifically binds to the p19-subunit of IL-23, is approved to treat psoriasis. Through Week24 (W24) of the Ph3,…
  • Abstract Number: 0501 • ACR Convergence 2020

    Structural Entheseal Lesions in Psoriasis Patients Are Associated with an Increased Risk Ofprogression to Psoriatic Arthritis – A Prospective Cohort Study

    David Simon1, Koray Tascilar1, Arnd Kleyer1, Sara Bayat2, Eleni Kampylafka2, Axel Hueber3, Juergen Rech1, Louis Schuster1, Klaus Engel4, Michael Sticherling2 and Georg Schett5, 1Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, 2Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, 3Sozialstiftung Bamberg, Sektion Rheumatologie, Bamberg, Germany, 4Siemens Healthcare GmbH Digital Technology & Camp; Innovation, SHS DS DTI, Erlangen, Germany, 5Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany

    Background/Purpose: We have previously reported that the presence of musculoskeletal pain in psoriasis patients is associated with a higher risk of developing psoriatic arthritis (PsA)…
  • Abstract Number: 0509 • ACR Convergence 2020

    Classification of Patients with Relapsing Polychondritis Based on Somatic Mutations in UBA1

    Marcela Ferrada1, Keith Sikora2, Sinisa Savic3, Yiming Luo4, Kristina Wells5, Emily Rose1, Kaitlin Quinn6, Wendy Goodspeed1, Anne Jones7, Mimi Le8, Amanda Ombrello9, Zuoming Deng10, Massimo Gadina11, Wanxia Tsai12, Ivona Aksentijevich7, Daniel Kastner13, David Beck14 and Peter C. Grayson15, 1Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2National Institutes of Health Clinical Center, Bethesda, MD, 3University of Leeds, England, United Kingdom, 4Rheumatology Fellowship and Training Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, 5Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, 6Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Washington, DC, 7National Human Genome Research Institute, Bethesda, MD, 8Oregon Health & Science University, Portland, 9National Institutes of Health, Bethesda, 10National Institute of Arthritis Musculoskeletal and Skin diseases, Bethesda, 11National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, MD, 12National Institute of Arthritis Musculoskeletal and Skin diseases, Bethesda, MD, 13National Human Genome Research Institute (NHGRI), NIH, Bethesda, MD, 14National Human Genome Research Institute, Bethesda, 15Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD

    Background/Purpose: Relapsing polychondritis (RP) is a rare, heterogenous, systemic inflammatory disease with a predilection for cartilaginous structures. Recently we discovered myeloid-restricted somatic mutations in UBA1 in…
  • « Previous Page
  • 1
  • …
  • 658
  • 659
  • 660
  • 661
  • 662
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology